All In Biotech

Drug Trial Radar · NCT06828848

A Study to Assess How Vaborem® is Taking up in the Body and Tolerated in Paediatric Patients With Gram Negative Infections, Including But Not Restricted to Complicated Urinary Tract Infections

An Open-label, Multicentre, Single-Arm Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of VaboremⓇ (Meropenem-Vaborbactam) in Paediatric Population With Suspected or Confirmed Gram Negative Infections, Including But Not Restricted to Complicated Urinary Tract Infections

Last checked: Nov 20, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

44

Planned (sponsor's estimate)

Start

Feb 18, 2025

Primary completion

Oct 2027

Study completion Oct 2027

Sponsor

Lead sponsor
Menarini GroupIndustry
Sponsor type
Industry
First posted
Feb 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 0 months, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to assess the pharmacokinetic (PK) and safety and tolerability of Vaborem (fixed combination of meropenem and vaborbactam) in the paediatric population aged from birth to \< 18 years with suspected or confirmed Gram negative infections in need of hospitalisation and intravenous (IV) antibiotic administration. All participants will receive Vaborem IV every 8 hours to treat the suspected or confirmed Gram negative infections for 10 up to 14 days; switch to stepdown oral antibiotic is allowed after a minimum of 3 days of Vaborem. PK sample collection will occur after at least 6 doses administration. Participant's clinical conditions will be monitored during the entire duration of the hospitalization and during scheduled visit/s after the completion of the treatment.

Conditions

  • Gram Negative Infections

Interventions

  • Meropenem plus vaborbactamDrug

    Meropenem plus vaborbactam fixed dose combination adjusted by body weight up to 2g/2g

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the concentration-time curve (AUC) for MeropenemTime frame: Day 3
  2. Area under the concentration-time curve (AUC) for VaborbactamTime frame: Day 3
  3. Maximum plasma concentration (Cmax) for MeropenemTime frame: Day 3
  4. Maximum plasma concentration (Cmax) for VaborbactamTime frame: Day 3
  5. Clearance (CL) of MeropenemTime frame: Day 3
  6. Clearance (CL) of VaborbactamTime frame: Day 3
  7. Half-life (t1/2) of MeropenemTime frame: Day 3
  8. Half-life (t1/2) of VaborbactamTime frame: Day 3
  9. Steady-state volume of distribution (Vss) of MeropenemTime frame: Day 3
  10. Steady-state volume of distribution (Vss) of VaborbactamTime frame: Day 3

Locations

22 sites in 5 countries. Site status is shown where the registry gives one.

  • Fakultni nemocnice Ostrava

    Ostrava, Czechia · Terminated

  • Faculty Hospital Kralovske Vinohrady, Paediatric Clinic

    Prague, Czechia · Terminated

  • Hôpital mère-enfant - CHU de Nantes

    Nantes, France · Recruiting

  • Nice University Hospital (CHU de Nice)

    Nice, France · Recruiting

  • Hospital Armand Trousseau Clinical Research Site

    Paris, France · Terminated

  • Hôpital Robert Debré

    Paris, France · Recruiting

  • CHRU de Tours Hôpital Clocheville Clinical Research Site

    Tours, France · Terminated

  • Policlinico di Bari

    Bari, Italy · Recruiting

  • Ospedale Sant'Orsola

    Bologna, Italy · Recruiting

  • Giannina Gaslini Institute

    Genoa, Italy · Terminated

  • Azienda Ospedaliero-Universitaria di Parma

    Parma, Italy · Recruiting

  • Ospedale Pediatrico Bambino Gesù

    Rome, Italy · Recruiting

  • Ospedale Regina Margherita

    Torino, Italy · Recruiting

  • Insytut Centrum Zdrowia Matki Polki / Polish Mother´s Memorial Hospital Research Institute (ICZMP)

    Lodz, Poland · Terminated

  • Uniwersyteckie Centrum Kliniczne WUM

    Warsaw, Poland · Recruiting

  • Wojskowy Instytut Medyczny - Państwowy Instytut Badawczy

    Warsaw, Poland · Recruiting

  • Hospital Sant Joan de Deu

    Barcelona, Spain · Recruiting

  • Hospital Universitario Puerta del Mar

    Cadiz, Spain · Recruiting

  • Hospital Dr Josep Trueta

    Girona, Spain · Recruiting

  • Hospital General Universitario Gregorio Marañón

    Madrid, Spain · Recruiting

  • Hospital Regional Universitario de Málaga

    Málaga, Spain · Terminated

  • Hospital Clinico Universitario de Santiago de Compostela

    Santiago de Compostela, Spain · Terminated

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.